Pathway for Softgel vs Tablet Comparison [Design Issues]

posted by Obinoscopy  – USA, 2018-05-15 19:04 (929 d 05:19 ago) – Posting: # 18764
Views: 2,007

Dear bebac_fan,

» I think this would need to go through a NDA/505(b)(2) pathway rather than an ANDA.

I share the same view with you on this.

However I have a case where a BE study was conducted comparing Metronidazole tablet (Reference) with Metronidazole soft gel (test). Both were IR. Is this acceptable?



Complete thread:

 Admin contact
21,220 posts in 4,427 threads, 1,481 registered users;
online 13 (0 registered, 13 guests [including 12 identified bots]).
Forum time: Sunday 23:23 CET (Europe/Vienna)

Half the harm that is done in this world
Is due to people who want to feel important.    T. S. Eliot

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz